Droperidol Plus Diphenhydramine for Symptom Improvement in Suspected Cannabinoid Hyperemesis Syndrome: A Prospective Cohort Study

Abstract Background: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by recurrent, paroxysmal episodes of nausea, vomiting, and abdominal discomfort in chronic cannabis users. Optimized CHS treatment data remain limited. Recent prospective evidence have demonstrated haloperidol superiority over ondansetron. Retrospective data suggest the utility of droperidol, a dopamine antagonist like haloperidol, for treating acute CHS. Objective: To prospectively assess the utility of droperidol plus diphenhydramine to mitigate common CHS symptoms. Methods: This was a multicenter, prospective interventional study in the emergency department